J&J's 'Texas two-step' talc bankruptcy case heads back to appeals court – Endpoints News

In late Feb­ru­ary, John­son & John­son won a con­tro­ver­sial case sur­round­ing its bank­rupt­cy fil­ing de­signed to set­tle 38,000 law­suits ac­cus­ing its talc-based prod­ucts of caus­ing can­cer. How­ev­er, it ap­pears that bank­rupt­cy case is far from over as the US ap­peals court has now agreed to re­vis­it that rul­ing.
The dis­pute stems from J&J’s use of a “Texas Two-step”: ap­ply­ing a law that en­abled it to spin out its li­a­bil­i­ties re­lat­ed to the on­go­ing talc law­suits in­to a sep­a­rate com­pa­ny. That com­pa­ny, known as LTL Man­age­ment, then filed for bank­rupt­cy — a move that shield­ed LTL (and there­fore J&J) from fur­ther ju­di­cial ac­tion in the talc law­suits.
The claimants in the case said that J&J’s moves are a mis­use of the US bank­rupt­cy code, though J&J main­tained that pre­vi­ous com­pa­nies have done the same.
The law­suits al­lege that J&J’s wide­ly-used ba­by pow­der and oth­er talc-based prod­ucts were con­t­a­m­i­nat­ed with as­bestos and caused mesothe­lioma and ovar­i­an can­cer.
Judge Michael Ka­plan of New Jer­sey, where J&J is head­quar­tered, sided with J&J in the bank­rupt­cy case, who said at the time J&J’s fil­ing “with the ex­pressed aim of ad­dress­ing the present and fu­ture li­a­bil­i­ties as­so­ci­at­ed with on­go­ing glob­al per­son­al in­jury claims to pre­serve cor­po­rate val­ue is un­ques­tion­ably a prop­er pur­pose un­der the Bank­rupt­cy Code.”
How­ev­er, Ka­plan lat­er grant­ed ex­pe­dit­ed ap­peal to the case, al­low­ing it to skip dis­trict courts and head di­rect­ly to the 3rd US Cir­cuit Court of Ap­peals, which has now agreed to re­view the case.
J&J stopped sell­ing its ba­by pow­der in 2020, though the megaphar­ma said it was due to de­clin­ing sales. The com­pa­ny has main­tained that its icon­ic talc prod­ucts do not con­tain as­bestos.
The phar­ma is al­so fac­ing a sep­a­rate law­suit in New Jer­sey from the fam­i­ly of a for­mer work­er that al­leges the com­pa­ny hid ev­i­dence of the pres­ence of as­bestos at a for­mer J&J sub­sidiary. In that case, Ka­plan ruled that J&J’s bank­rupt­cy fil­ing did not ap­ply.
The mesothe­lioma claimants com­mit­tee de­clined to com­ment on the ap­peals up­date. John­son & John­son did not re­spond to a re­quest for com­ment be­fore pub­li­ca­tion.
How are top investors navigating the longest biotech bear market in almost 20 years? RBC Capital Markets Healthcare Desk Sector Strategist Chris McCarthy discusses key fundamentals, macro-awareness and the continued impact of COVID with HealthCor’s Ben Snedeker and Omega Funds founder Otello Stampacchia.
Biotech indexes may be down, but both Snedeker and Otello Stampacchia, Ph.D., Founder and Managing Director of Omega Funds, see opportunities in the market. In Snedeker’s opinion, investors need to seek out companies with the potential for meaningful revenue growth, particularly those that are mispriced in the current bear market.
Gout is the most common form of inflammatory arthritis, but not many people make the connection. That’s why Horizon Therapeutics is partnering with the Arthritis Foundation in a new campaign that includes outdoor murals in cities across the US. In each of the four artworks, the uric acid crystals that build up inside the body with gout are shown as bright green crystals on hands, feet or spine.
The murals include Horizon’s campaign website uncovergout.com where people can see a behind-the-scenes video about the condition and the making of the images, along with more information and patients’ stories about the stigma and misconceptions around gout.
Unlock this story instantly and join 142,000+ biopharma pros reading Endpoints daily — and it’s free.
Three generic drugmakers have ceased operations immediately, as their holding company has enlisted a consulting firm to oversee the process of administration as 1,000 employees lose their jobs.
Doncaster Pharmaceuticals Group, Testerworld, and Eclipse Generics have brought on the consulting firm Kroll as it winds down its operations. The three wholesalers are all a part of the Converse Pharma Group, a major supplier of drugs that has more than 4,000 customers.
Unlock this story instantly and join 142,000+ biopharma pros reading Endpoints daily — and it’s free.
Roche is ending the week with another dispiriting setback to reflect on.
Right on the heels of its big TIGIT Phase III fail, which rattled the company from top to bottom as its share price was hammered, Sandoz announced it’s rolling out the first knockoff of their blockbuster IPF drug Esbriet.
This is the first fully substitutable copy of the drug, which has been playing second fiddle to Ofev from Boehringer Ingelheim, which earned $2.7 billion last year, compared to a bit more than a billion dollars for the Roche drug. And Sandoz is doing the launch with a 0-dollar co-pay from qualified patients.
Unlock this story instantly and join 142,000+ biopharma pros reading Endpoints daily — and it’s free.
Bristol Myers Squibb’s manufacturing facility in East Syracuse, NY, is about to be swallowed up by one of the largest conglomerates in South Korea.
Lotte Corporation and BMS unveiled a fresh deal for the site on Friday while keeping most of the details — including the financing — under wraps. BMS even declined to disclose the site’s square footage in an email to Endpoints News. 
Meanwhile, South Korea’s Yonhap News Agency reported that the deal cost Lotte $160 million. In return, the conglomerate gets the site, equipment and a workforce with “technical capabilities and expertise.”
Both GlaxoSmithKline and iTeos Therapeutics are going to take a hard look at their experimental TIGIT-targeting immunotherapy in the wake of Roche’s fail earlier this week.
EOS-448, an IgG1anti-TIGIT monoclonal antibody designed to engage the Fc gamma receptor (FcγR), is being “reevaluated” by the partners, iTeos revealed in its first quarter financial report Thursday. And there may even be further delays going forward: According to an iTeos company spokesperson in an email to Endpoints News, the three registration-directed trials that were due to potentially kick off around the end of the year now will have to wait until next year.
Unlock this story instantly and join 142,000+ biopharma pros reading Endpoints daily — and it’s free.
Checkmate Pharmaceuticals knew time was running out to fund the future of its sole asset. The cash reserves at Art Krieg’s I/O biotech would run out as the clock struck 2023, and it didn’t help that Checkmate had struggled to attract institutional investor interest in 2021 and again couldn’t eke out any semblance of acquisition appetite from five “global pharmaceutical companies.”
Unlock this story instantly and join 142,000+ biopharma pros reading Endpoints daily — and it’s free.
As Teva is facing opioid litigation and potential settlements in the US, it is now facing more litigation on the other side of the world — on its own turf.
First reported by Globes, the State of Israel filed a lawsuit Wednesday in a district court seeking a $100 million judgment against Teva, with the state claiming that the company violated the state’s rights to certain research by not paying royalties for Copaxone, a blockbuster multiple sclerosis treatment that Teva retains marketing rights for.
Caribou Biosciences just flipped its first card on human data for its lead off-the-shelf anti-CD19 CAR-T, and it’s an ace.
The biotech reported out on a tiny group of patients — just five treatment-resistant individuals suffering from B cell non-Hodgkin’s lymphoma in this first round — and came up with a 100% overall response rate with an 80% complete response rate.
Those headline numbers quickly registered as a rare win these days in the bleak biotech sector, as Caribou’s share price $CRBU surged 25%.
Unlock this story instantly and join 142,000+ biopharma pros reading Endpoints daily — and it’s free.
Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas
© Endpoints Company 2022
If you’re already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.
We’ll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.
ENDPOINTS NEWS Daily at 11:30 AM ET
EARLY EDITION Daily at 7:15 AM ET
ENDPOINTS PHARMA Daily at 2 PM ET
ENDPOINTS MARKETING RX Tue at 2 PM ET
ENDPOINTS FDA+ Wed at 2 PM ET
ENDPOINTS MANUFACTURING Thu at 2 PM ET
ENDPOINTS WEEKLY Sat at 6 AM ET

source

Related posts

Leave a Reply

Your email address will not be published.